CliffBio
biologic

Tysabri

natalizumab

Loss of exclusivityNovember 2016projected — 12-year biologic exclusivity estimate
CompanyBiogen →See this company's full patent-cliff portfolio

Drug detail

Brand nameTysabri
Active ingredientnatalizumab
Strength300MG/15ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2004
Marketing statusRx

More from Biogen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tysabri patent cliff — loss of exclusivity November 2016 | CliffBio